



ORIGINAL ARTICLE

Headache as the sole presenting symptom of cerebral venous sinuses thrombosis: Subgroup analysis of data from the VENOST study

Tek semptomu baş ağrısı olan serebral venöz sinüs trombozu: VENOST çalışmasından elde edilen verilerin alt grup analizi

İD Taşkın DUMAN,¹ İD Nilgün ÇINAR,² İD Derya ULUDÜZ,³ İD Füsün MAYDA DOMAÇ,⁴ İD Serefnur ÖZTÜRK,⁵ İD Vildan YAYLA,⁶ İD Ali Yavuz KARAHAN,⁷ İD Nazire AFŞAR,⁸ İD Mehmet Ali SUNGUR,⁹ İD Eylem ÖZAYDIN GÖKSU,¹⁰ İD Vedat Ali YÜREKLİ,¹¹ İD Hamit GENÇ,¹² İD Uygur UTKU,¹³ İD Şevki ŞAHİN,² İD Hakan TEKELİ,¹⁴ İD Firdevs Ezgi TOKUÇ,¹⁰ İD Nevzat UZUNER,¹⁵ İD Mehmet Güney ŞENOL,¹⁴ İD Arda YILMAZ,¹² İD Mustafa GÖKÇE,¹³ İD Seden DEMİRCİ,¹¹ İD Özge YILMAZ KÜSBECİ,¹⁶ İD Gülnur TEKGÖL UZUNER,¹⁵ İD Hale Zeynep BATUR ÇAĞLAYAN,¹⁷ İD Mustafa AÇIKGÖZ,¹⁸ İD Hatice KURUCU,¹⁹ İD Mehmet Fatih ÖZDAĞ,¹⁴ İD Sevim BAYBAŞ,²⁰ İD Hakan EKMEKÇİ,⁵ İD Murat ÇABALAR,⁶ İD Mehmet YAMAN,²¹ İD Hesna BEKTAŞ,²² İD Yüksel KAPLAN,²³ İD Başak KARAKURUM GÖKSEL,²⁴ İD Aysel MİLANLIOĞLU,²⁵ İD Dilek NECİOĞLU ÖRKEN,²⁶ İD Mehmet Ufuk ALUCLU,²⁷ İD Sena ÇOLAKOĞLU,¹ İD Ahmet TÜFEKÇİ,²⁸ İD Mustafa BAKAR,²⁹ İD Bijen NAZLIEL,¹⁷ İD Nida TAŞÇILAR,¹⁸ İD Baki GÖKSAN,³ İD Hasan Hüseyin KOZAK,³⁰ İD Cemile Handan MISIRLI,³¹ İD Hayriye KÜÇÜKOĞLU,²⁰ İD İpek MİDİ,³² İD Necdet MENGÜLLÜOĞLU,³³ İD Emrah AYTAÇ,³⁴ İD Nilüfer YEŞİLOT,³⁵ İD Birsen İNCE,³ İD Osman Özgür YALIN,³⁶ İD Taşkın GÜNEŞ,³⁷ İD Serdar ORUÇ,²¹ İD Serkan DEMİR³⁸

¹Department of Neurology, Mustafa Kemal University, Hatay, Turkey; ²Department of Neurology, Maltepe University, İstanbul, Turkey; ³Department of Neurology, İstanbul Cerrahpaşa University, İstanbul, Turkey; ⁴Department of Neurologic and Psychiatric Diseases, Erenköy Training and Research Hospital for Neurologic and Psychiatric Diseases, İstanbul, Turkey; ⁵Department of Neurology, Selçuk University, Konya, Turkey; ⁶Department of Neurology, Bakırköy Training and Research Hospital, İstanbul, Turkey; ⁷Department of Physical Medicine and Rehabilitation, Uşak University, Uşak, Turkey; ⁸Department of Neurology, Acibadem University, İstanbul, Turkey; ⁹Department of Biostatistics, Düzce University, Düzce, Turkey; ¹⁰Department of Neurology, Antalya Training and Research Hospital, Antalya, Turkey; ¹¹Department of Neurology, Süleyman Demirel University, Isparta, Turkey; ¹²Department of Neurology, Mersin University, Mersin, Turkey; ¹³Department of Neurology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey; ¹⁴Department of Neurology, Sultan Abdülhamid Han Training and Research Hospital, İstanbul, Turkey; ¹⁵Department of Neurology, Osmangazi University Faculty of Medicine, Eskişehir, Turkey; ¹⁶Department of Neurology, Bozyaka Education, Research and Training Hospital, İzmir, Turkey; ¹⁷Department of Neurology, Gazi University Faculty of Medicine, Ankara, Turkey; ¹⁸Department of Neurology, Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey; ¹⁹Dementia Research Institute, Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh W1T 7NF, UK; ²⁰Department of Neurology, Bakırköy Training and Research Hospital for Neurologic and Psychiatric Diseases, İstanbul, Turkey; ²¹Department of Neurology, Kocatepe University Faculty of Medicine, Afyon, Turkey; ²²Department of Neurology, Atatürk Training and Research Hospital, Ankara, Turkey; ²³Department of Neurology, İnönü University Faculty of Medicine, Malatya, Turkey; ²⁴Department of Neurology, Başkent University Faculty of Medicine, Adana, Turkey; ²⁵Department of Neurology, Yüzüncü Yıl University Faculty of Medicine, Van, Turkey; ²⁶Department of Neurology, İstanbul Bilim University Faculty of Medicine, İstanbul, Turkey; ²⁷Department of Neurology, Dicle University Faculty of Medicine, Diyarbakır, Turkey; ²⁸Department of Neurology, Recep Tayyip Erdoğan University Faculty of Medicine, Rize, Turkey; ²⁹Department of Neurology, Uludağ University Faculty of Medicine, Bursa, Turkey; ³⁰Department of Neurology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey; ³¹Department of Neurology, Health Sciences University Haydarpaşa Training and Research Hospital, İstanbul, Turkey; ³²Department of Neurology, Marmara University Faculty of Medicine, İstanbul, Turkey; ³³Department of Neurology, Eskişehir State Hospital, Eskişehir, Turkey; ³⁴Department of Neurology, Ankara Training and Research Hospital, Ankara; ³⁵Department of Neurology, İstanbul University, İstanbul Faculty of Medicine, İstanbul, Turkey; ³⁶Department of Neurology, Health Sciences University, İstanbul Training and Research Hospital, İstanbul, Turkey; ³⁷Department of Neurology, Maltepe State Hospital, İstanbul, Turkey; ³⁸Department of Neurology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey

Submitted (Başvuru tarihi) 16.01.2020 Accepted after revision (Düzeltilme sonrası kabul tarihi) 15.04.2020 Available online date (Online yayımlanma tarihi) 11.01.2021

Correspondence: Dr. Nilgün Çınar. Maltepe Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Turkey

Phone: +90 - 216 - 442 96 82 **e-mail:** cinarnilgun@gmail.com

© 2021 Turkish Society of Allogology

Summary

Objectives: Headache is the most common complaint in cerebral venous sinus thrombosis (CVST) and it may sometimes be the only symptom in these patients. This retrospective and prospective study was an investigation of any differences in terms of clinical risk factors, radiological findings, or prognosis in patients with CVST who presented with isolated headache (IH) and cases with other concomitant findings (non-isolated headache [NIH]).

Methods: A total of 1144 patients from a multicenter study of cerebral venous sinus thrombosis (VENOST study) were enrolled in this research. The demographic, biochemical, clinical, and radiological aspects of 287 IH cases and 857 NIH cases were compared.

Results: There were twice as many women as men in the study group. In the IH group, when gender distribution was evaluated by age group, no statistically significant difference was found. The onset of headache was frequently subacute and chronic in the IH group, but an acute onset was more common in the NIH group. Other neurological findings were observed in 29% of the IH group during follow-up. A previous history of deep, cerebral, or other venous thromboembolism was less common in the IH group than in the NIH group. Transverse sinus involvement was greater in the IH group, whereas sagittal sinus involvement was greater in the NIH group. The presence of a plasminogen activator inhibitor (PAI) mutation was significantly greater in the IH group.

Conclusion: IH and CVST should be kept in mind if a patient has subacute or chronic headache. PAI, which has an important role in thrombolytic events, may be a risk factor in CVST. Detailed hematological investigations should be considered. Additional studies are needed.

Keywords: Cerebral venous sinus thrombosis; cerebrovascular disease; headache.

Özet

Amaç: Baş ağrısı serebral venöz sinüs trombozunda (SVST) en sık görülen şikayettir ve bazen CVST ile başvuran hastalarda görülen tek semptom olabilir. Bu retrospektif ve prospektif çalışmada, izole baş ağrısı (İB) ile başvuran SVST olgularında ve baş ağrısı ile ilişkili diğer bulguları olan (izole olmayan baş ağrısı-İOBA) olgularda klinik risk faktörleri, radyoloji ve prognoz açısından herhangi bir farklılık olup olmadığını araştırdık.

Gereç ve Yöntem: Serebral venöz sinüs trombozu (VENOST) çok merkezli çalışmasından 1144 hasta çalışmamıza alındı. Tüm demografik, biyokimyasal, klinik ve radyolojik yönler 287 İBA vakası ve 857 İOBA vakası için karşılaştırılmıştır.

Bulgular: Toplam grup içinde kadın oranı iki kat daha yüksekti. İBA grubunda cinsiyet dağılımını yaş gruplarına göre değerlendirildiğinde istatistiksel olarak anlamlı bir fark bulunmadı. İBA grubunda, baş ağrısının başlangıcı sıklıkla subakut ve kronikti, ancak akut başlangıç, İOBA grubunda daha yaygındı. İBA grubunda %29'luk takip sırasında diğer nörolojik bulgular eklenmiştir. Daha önce serebral, derin ve diğer venöz tromboembolizm öyküsü İBA grubunda İOBA grubuna göre daha azdı. Transvers sinüs tutulumu İBA grubunda daha yüksek iken sagittal sinüs tutulumu İOBA grubunda daha fazlaydı. Plasminojen aktivatör inhibitörü (PAI) mutasyonu İBA grubunda anlamlı olarak daha yüksekti.

Sonuç: Hastaların subakut veya kronik baş ağrısı varsa SVST tanısı için İBA akılda tutulmalıdır. Trombolitik olaylar için önemli bir role sahip olan PAI, SVST'da bir risk faktörü olabilir, bu nedenle ayrıntılı hematolojik araştırmalar düşünülmelidir. Daha ileri çalışmalara ihtiyaç vardır.

Anahtar sözcükler: Serebrovasküler hastalık; baş ağrısı; serebral venöz sinüs trombozu.

Introduction

Patients may present with various symptoms as a result of cerebral venous sinus thrombosis (CVST) of dural venous sinuses and deep and superficial cerebral veins thrombosis.^[1] CVST can mimic other diseases with different clinical manifestations ranging from headache to coma. CVST may present with a single finding or may be seen as a syndrome consisting of many findings. Clinically unclear process may complicate the diagnosis of CVST.^[2,3]

In many studies, it has been reported that headache is seen in more than 80% of the cases is the most common first symptom. Headache in CVST is not typical and other neurological symptoms such as seizures, papilloedema, focal deficits, cranial nerve paralysis or impaired consciousness can be added to headache.^[4]

The mechanism of headache in CVST is not known when there is not intracranial hypertension, sub-

arachnoid haemorrhage (SAH), meningitis or intracranial lesion.

There is a possibility that nerve fibers are affected in the obstructed sinuses. In addition, it is possible to have contrast involvement around the clot, which is known as the 'empty delta sign' which is a dilatation of the vessels as a result of local inflammation of the sinuses.^[4,5]

Rarely, headache in CVST may not be associated with any clinical findings. However brain computed tomography (CT) scanning and/or cerebrospinal fluid (CSF) examination usually reveal the conditions such as SAH, intracerebral infarction or haemorrhage that can be the cause of headache of CVST. In the absence of such conditions in CVST, it is rare to have only headache complaints.^[6-8]

In this study, we presented the characteristics of 1144 patients in whom headache was the only clini-

cal presentation of CVST in the absence of other aetiological factors which are assessed by imaging tests. Also the aim of this study was to investigate the clues for the diagnosis of CVST only in patients with headache.

Material and Methods

Patient selection

The study design of cerebral venous thrombosis (VENOST), an international multicentre observational study involving 1144 patients who were retrospectively diagnosed with CVST between June 2000 and June 2015, was described in detail.^[9] The study was approved by the ethics committee of the centers (no: 83045809/604/02-12333).

This study includes all members of the VENOST group. In VENOST, CVST was diagnosed based on the patient's clinical findings and the presence of thrombosis in the cerebral venous sinuses detected using brain computed tomography (CT), brain magnetic resonance imaging (MRI), MR venography (MRV) and/or digital subtraction angiography (DSA).

The patients were divided into two groups according to headaches such as; the cases with CVST that comes with only headache (isolated headache-IH) and cases with other findings in addition to headache (non-isolated headache-NIH).

Both groups were compared according to their initial clinical findings on admission, etiologic factors, imaging findings and prognostic factors.

Research on thrombotic risk factors was performed in 63.7% of the participating centers.^[10] Methylenetetrahydrofolate reductase (MTHFR), prothrombin mutation, plasminogen activator inhibitor (PAI) mutation, Factor V Leiden mutation test was performed in 729 patients; Antiphospholipid Ab, hyperhomocysteinemia, hyperfibrinogenemia, antithrombin III and protein C/S deficiency, activated protein C resistance, antinuclear antibody (ANA) positivity, thrombocytosis, anticardiolipin Ab were measured in 941 patients.^[9]

Etiological risk factors such as infections, systemic inflammatory diseases, rheumatologic or connective tissue diseases, malignancy, hematologic diseases and the other causes were also recorded.

On admission, the duration of symptoms was accepted as acute if the duration is less than 48 hours, subacute between 48 hours and 1 month and chronic if the duration of symptoms was more than 1 month.

Follow-up examination results were classified according to the modified Rankin Scale (mRS). mRS score was classified as 0–1 independent (favorable outcome), mRS score 2 minimum disability and mRS score 3–6 dependent or dead (poor outcome).

The visits of the cases were recorded 1, 3, 6 and 12 months after the initial diagnosis of CVST.

Results

Mean age and female/male ratio of IH group (n: 287, 25.1%) were 40.1 ± 13.3 years and 185/102; NIH group (n: 857, 74.9%) were 40.04 ± 13.8 years and 592/265 respectively. Statistically meaningful age difference was not detected between IH and NIH groups (Table 1).

In the IH group, when evaluated the gender distribution by age groups, there was no statistically significant difference ($p=0.115$). In the NIH group, the ratio of female/male between the ages of 18–36 was found equal (female/male ratio: 46/46%), the ratio of female in the 37–50 year-old group was higher (female/male ratio: 37/26%); in the age group >50 years and the ratio of male was significantly higher (female/male ratio: 17/28%) ($p<0.001$).

In the IH group, onset of headache was frequently subacute and chronic, but an acute onset was more common in the NIH group (Table 1).

Detailed radiological evaluation (MRI and MRV) was performed in 92% of the IH group and 88.1% of the NIH group. Only MR, MRV, CT + MRV were performed in other cases (Table 1).

It was seen that 10 (29%) patients in IH group had additional neurological findings including nausea, vomiting, epileptic seizures, visual field defect, focal neurological deficit, altered consciousness and cranial nerve palsies during follow-up. In the NIH group neurological findings were existed at the beginning

In IH group there was no difference according to existence of parenchymal lesions. In the NIH group,

parenchymal lesions as infarction, hemorrhage and hemorrhagic transformation were seen more often than the other group (Table 1).

A previous cerebral, deep and other venous thromboembolism history was less common in IH group than the NIH group (Table 2).

Transverse sinus involvement was higher in IH group, whereas sagittal sinus involvement was higher in NIH group.

The prognosis of IH group was better than NIH group according to mRS.

When the hematological parameters were examined, plasminogen activator inhibitor (PAI) mutation was significantly higher in IH group (Table 2).

Discussion

CVST is a complicated process because it may present with different clinical situations.^[11] Rarely CVST may occur with headache alone and there may not always be an additional finding so that CVST may usually be thought to be secondary headache disorders.^[12] Headache was reported to be the most common symptom in 92% of CVST cases in a study. In addition, approximately one-third of patients reported only sole manifestation.^[13] In our study, headache was the only onset symptom in one third of the patients. Our results were consistent with the previous studies. In CVST, 84% of headaches begin as acute to subacute, while 20% had a chronic onset.^[7,14,15] In our IH group, 33% of CVST cases had chronic type headache.

CVST diagnosis may be made earlier in the patient who comes to the hospital with changes in consciousness, mental disorders and seizures,^[7] but care should be taken to avoid misdiagnosis by taking into account the unfamiliar initial pattern in CVST patients with chronic headache. The possibility of CVST should be considered if a chronic intermittent headache worsens or if a new onset chronic headache develops.^[14,15] For this reason, patients with subacute or chronic headache should still be examined and venous thrombosis should also be kept in mind. Therefore, detailed radiological evaluation helps in diagnosis and affects treatment positively.

Because of this CT with or without contrast may not be sensitive enough to rule out CVST in patients with headache. The remarkable use of MRI and especially the increase in the use of MRV has made this diagnosis easier.^[11] In previous studies, it is shown that MRI combine with MRV are current diagnostic modality of choice and are the best imaging technique for diagnosis of CVST in patients with unclear findings on CT.^[16,17] DSA is the more effective for early diagnosis of dural sinus lesions but the American Heart and Stroke Association recommend MRI and MRV as a preferred tests for the diagnosis of dural sinus lesions.^[18] In our study, 92.3% patients underwent detailed radiological work-ups, including MRI and MRV to put the diagnosis easily.

Patients with CVST may present with variable neurological findings, but usually epileptic seizures, focal neurological deficits and encephalopathy are more common. In a study, focal or generalised seizures occur in 30–50%, papilloedema in 30–60% of CVST patients approximately 10% of patients are comatose at the time of diagnosis.^[7,9,19] In our study, epileptic seizures, visual field defects, focal neurological deficits were more common in the NIH group and altered consciousness was found to be 24% of patients.

CVST is usually more common in women than men. In a study it is analyzed that 75% of patients were women.^[20] It is seen more often in middle-aged women. In our study when all 1144 patients were evaluated in terms of gender, women were more in the group. Also, most of them were in the middle-aged group.

The cerebral venous system consists of superficial and a deep parts. The superior sagittal and transverse sinuses form the superficial cerebral venous system. Lateral sinus, straight sinus and sigmoid sinus are parts of deeper system.^[21] The transverse and superior sagittal sinuses are commonly affected sinuses in CVST.^[7] Transverse sinus is the most commonly affected sinus in 77% of cases in a study.^[16] In our study, the most effected sinus was transverse sinus in both groups similar to the other studies. However sagittal sinus involvement was higher in NIH group than IH group.

There may be various factors in the etiology of CVST. Genetic and prothrombotic disorders may be among

Table 1. Compared data of demographical and clinical aspects of both groups

	Non-isolated headache (NIH)		Isolated headache (IH)		p
	n=857	75%	n=287	25%	
Age (years)	40.04±13.82		40.15±13.39		0.911
18–36 (years)	397	46.3	136	47.4	0.499
37–50	292	34.1	88	30.7	
>51	168	19.6	63	22	
Gender					0.147
Female	592	69.1	185	64.5	
Male	265	30.9	102	35.5	
Mode of onset					<0.001
Acute	442	52.5 ^a	88 ^b	31	
Subacute	280	33.3 ^a	103 ^a	36.3	
Chronic	120	14.3 ^a	93 ^b	32.7	
Clinical symptoms and signs					<0.001
Headache	710	82.8	287	100	
Nausea and vomiting	317	37	0	0	
Epileptic seizures	270	31.5	1	0.3	
Visual field defect	298	34.8	5	1.7	
Focal neurological deficit	207	24.2	1	0.3	
Altered consciousness	203	23.7	1	0.3	
Cranial nerve palsies	126	14.7	2	0.7	
Radiological work-up					0.115
Cranial MRI	50	5.9	10	3.5	
Cranial MRV	31	3.6	10	3.5	
Cranial MRI+MRV	752	88.1	263	92.3	
Cranial CT+ MRV	21	2.5	2	0.7	
Number of sinuses involved					0.185
1 sinus	401	46.8	150	52.3	
2 sinuses	302	35.2	85	29.6	
3 sinuses	125	14.6	46	16	
4 sinuses	29	3.4	6	2.1	
Involved sinuses					0.001
Isolated transverse sinuses	197	23	95	33.1	
Isolated sagittal sinuses	134	15.6	34	11.8	
Isolated sigmoid sinuses	26	3	11	3.8	
Isolated cortical veins	18	2.1	6	2.1	
Isolated Jugular sinuses	12	1.4	4	1.4	
Isolated cavernous sinuses	9	1.1	0	0	
Transverse sinuses	616	71.9	224	78	
Sigmoid sinuses	334	39	121	42.2	
Sagittal sinuses	369	43.1	76	26.5	
Internal jugular vein	131	15.3	47	16.4	
Cortical veins	32	3.7	10	3.5	
Cavernous sinuses	15	1.8	4	1.4	
Cavernous sinuses	15	1.8	4	1.4	
Parenchymal involvement					<0.001
No lesion	456	53.2 ^a	229 ^b	79.8	
Infarction	185	21.6 ^a	33 ^b	11.5	
Hemorrhagic infarction	180	21 ^a	18 ^b	6.3	
Intracerebral hemorrhage	36	4.2 ^a	7 ^a	2.4	

MRI: Magnetic resonance imaging; MRV: Magnetic resonance venography; CT: Computed tomography. One-way Anova test: Comparison of a and b: $p \leq 0.05$; comparison of a and a: $p > 0.05$.

Table 2. Etiological factors and outcome according to isolated headache and headache with other etiological factors

	Isolated headache (-)		Isolated headache (+)		p
	n=857	75%	n=287	25%	
Infections					
Paracranial (focal)	53	6.2	17	5.9	0.918
Systemic	18	2.1	5	1.7	
History of VTE					
Cerebral	24	2.8 ^a	2	0.7 ^b	0.045
Deep venous thrombosis	35	4.1 ^a	6	2.1 ^a	0.712
Other	7	0.8 ^a	1	0.3 ^a	0.075
Malignancy	43	5.0	16	5.6	
Family history VTE	11	1.3	0	0	0.168
MTHFR mutation					
Heterozygote	28	5	9	5.3	0.254
Homozygote	30	5.4	16	9.4	0.802
Hyperhomocysteinemia	31	4.3	14	6.2	0.133
Prothrombin mutation	15	2.7	4	2.3	0.599
Protein C/S deficiency	40	5.6	7	3.1	0.765
Factor V leiden mutation	27	4.8	10	5.8	0.692
Thrombocytosis	8	1.1	2	0.9	0.634
Polisitemia vera	6	0.8	1	0.4	<0.001
Anticardiolipin Ab	4	0.6	2	0.9	0.345
PAI mutation	2	0.4	8	4.7	0.583
Antithrombin III deficiency	5	0.7	0	0	0.744
Hyperfibrinogenemia	3	0.4	0	0	0.819
Antiphospholipid Ab	9	1.3	2	0.9	
Activated protein C resistance	11	1.5	3	1.3	0.291
High ANA titers	18	2.5	3	1.3	0.11
Behçet disease	74	8.8	34	12.8	0.402
SLE	12	1.4	3	1.1	
1st month					
0-1	569	73.6 ^a	218	94.4 ^b	<0.001
2	110	14.2 ^a	7	3 ^b	
≥3	94	12.2 ^a	6	2.6 ^b	
3rd month					
0-1	562	86.3 ^a	202	97.1 ^b	<0.001
2	51	7.8 ^a	3	1.4 ^b	
≥3	38	5.8 ^a	3	1.4 ^b	
6th month					
0-1	526	89.5 ^a	186	97.9 ^b	0.001
2	36	6.1 ^a	1	0.5 ^b	
≥3	26	4.4 ^a	3	1.6 ^a	
12th month					
0-1	481	91.3 ^a	162	98.8 ^b	0.004
2	22	4.2 ^a	0	0 ^b	
≥3	24	4.6 ^a	2	1.2 ^a	

ANA: Anti nuclear antibody; MTHFR: Methylenetetrahydrofolate reductase; PAI: Plasminogen activator inhibitor; VTE: Venous thromboembolism; SLE: Systemic Lupus Erythematosus. One-way Anova test: Comparison of a and b: $p \leq 0.05$; comparison of a and a: $p > 0.05$.

the causes of CVST.^[22] In a study, after a detailed examination of patients with cerebral venous thrombosis, 20–35% remains idiopathic.^[23] In our study, 44% of the IH group and 53% of the NIH group had no cause of thrombosis. It is shown that 85% of affected patients have at least one risk factor. Among the affected patients, 34% had a prothrombotic condition and 22% had genetic predisposition to the disease.^[6] Common hereditary factors are deficiency of antithrombin III, protein C or protein S, activated protein C resistance and prothrombin 20211A mutation.^[24] Rare defects include heparin cofactor II, plasminogen or tissue plasminogen activator deficiency, PAI-1 and dysfibrinogenemia.^[25] In our study, 37% in the IH group and 42% in the NIH group had prothrombotic conditions. Also, Behçet's disease was the most common cause of prothrombotic disease in both groups.^[10] As an interesting finding, the PAI mutation was significantly higher in the IH group. PAI is mainly important in regulating the fibrinolytic system. PAI-1 deficiency can cause abnormal bleeding in humans. Excessive release of PAI-1 may disrupt the normal fibrin formation mechanism in the vessel wall, leading to excessive accumulation of fibrin, resulting in thrombotic events.^[22,26] PAI-1 genotype polymorphism expresses PAI-1 at a higher rate and has a higher risk of deep vein thrombosis.^[27] In our study, we found that the PAI mutation in IH group was significantly higher than in the other group, but it should be supported by further studies.

It is reported that the outcomes of CVST were positive in 92% of the patients and the mortality rate was reported as 5.4%.^[28] Causes of poor prognosis include systemic or central nervous system infections and treatment inadequacies.^[29]

In our patients, the prognosis was good in both groups but it was better in the IH group.

Conclusion

CVST should be remembered in patients with only headache symptom, even if headache is subacute or chronic type. Therefore, MRI and MRV should be added to detailed radiological examinations. PAI, which has an important role for thrombolytic events, may be a risk factor in CVST. PAI mutation should be kept in mind in the evaluation for prothrombotic agents. Further studies are needed.

Ethics Committee Approval: The İstanbul University, Cerrahpaşa Faculty of Medicine Clinical Research Ethics Committee granted approval for this study (date: 06.05.2014, number: 83045809/604/02-12333).

Conflict-of-interest issues regarding the authorship or article: None declared.

Peer-review: Externally peer-reviewed.

References

1. Bushnell C, Saposnik G. Evaluation and management of cerebral venous thrombosis. *Continuum (Minneapolis)* 2014;20(2):335–51.
2. Aoun SG, Rahme RJ, Batjer HH, Bendok BR. New guidelines for the management of cerebral venous thrombosis. *Neurosurgery* 2011;69(2):N15–7.
3. Paciaroni M, Palmerini F, Bogousslavsky J. Clinical presentations of cerebral vein and sinus thrombosis. *Front Neurol Neurosci* 2008;23:77–88.
4. Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. *J Neurol Neurosurg Psychiatry* 2005;76(8):1084–7.
5. Shintani S, Murase H, Ota H, Tsukagoshi H, Shiozawa Z. "Pseudo-delta sign" on computed tomography in an extremely acute stage of superior sagittal sinus thrombosis—a case report. *Angiology* 1990;41(5):417–20.
6. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke* 2004;35(3):664–70.
7. Ferro JM, Canhão P. Cerebral venous sinus thrombosis: update on diagnosis and management. *Curr Cardiol Rep* 2014;16(9):523.
8. Gulati D, Strbian D, Sundararajan S. Cerebral venous thrombosis: diagnosis and management. *Stroke* 2014;45(2):e16–8.
9. Duman T, Uluduz D, Midi I, Bektas H, Kablan Y, Goksel BK, et al; VENOST Study Group. A Multicenter Study of 1144 Patients with Cerebral Venous Thrombosis: The VENOST Study. *J Stroke Cerebrovasc Dis* 2017;26(8):1848–57.
10. Uluduz D, Midi I, Duman T, Colakoglu S, Tüfekci A, Bakar M, et al. Behçet's disease as a causative factor of cerebral venous sinus thrombosis: subgroup analysis of data from the VENOST study. *Rheumatology (Oxford)* 2019;58(4):600–8.
11. Ravishankar K. Incidence and pattern of headache in cerebral venous thrombosis. *J Pak Med Assoc* 2006;56(11):561–4.
12. Alvis-Miranda HR, Milena Castellar-Leones S, Alcalá-Cerra G, Rafael Moscote-Salazar L. Cerebral sinus venous thrombosis. *J Neurosci Rural Pract* 2013;4(4):427–38.
13. Sparaco M, Feleppa M, Bigal ME. Cerebral Venous Thrombosis and Headache—A Case-Series. *Headache* 2015;55(6):806–14.
14. Luo Y, Tian X, Wang X. Diagnosis and Treatment of Cere-

- bral Venous Thrombosis: A Review. *Front Aging Neurosci* 2018;10:2.
15. Uzar E, Ekici F, Acar A, Yucel Y, Bakir S, Tekbas G, et al. Cerebral venous sinus thrombosis: an analyses of 47 patients. *Eur Rev Med Pharmacol Sci* 2012;16(11):1499–505.
 16. Anadure RK, Wilson V, Sahu S, Singhal A, Kota S. A study of clinical, radiological and etiological profile of cerebral venous sinus thrombosis at a tertiary care center. *Med J Armed Forces India* 2018;74(4):326–32.
 17. Issar P, Chinna S, Issar SK. Evaluation of Cerebral Venous Thrombosis by CT, MRI and MR Venography. *J Assoc Physicians India* 2017;65(11):16–21.
 18. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2011;42(4):1158–92.
 19. Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous thrombosis. *Nat Rev Neurol* 2017;13(9):555–65.
 20. Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Cantú C, Bousser MG, et al. Cerebral venous and sinus thrombosis in women. *Stroke* 2009;40(7):2356–61.
 21. Kiliç T, Akakin A. Anatomy of cerebral veins and sinuses. *Front Neurol Neurosci* 2008;23:4–15.
 22. Bindala S, Coskun O, Alioglu B, Inan LE, Sahin BE, Ocal R. Elevation of Blood Plasminogen Activator Inhibitor Level in Patients With Cerebral Venous Thrombosis. *J Neurol Res* 2018;8(1-2):4–9.
 23. Maksimova MY, Dubovitskaya YI, Shuvakhina NA. Clinical presentations, diagnosis and treatment of cerebral vein and sinus thrombosis. *Zh Nevrol Psikhiatr Im S S Korsakova* 2018;118(3. Vyp. 2):3–8. [Article in Russian]
 24. Pai N, Ghosh K, Shetty S. Hereditary thrombophilia in cerebral venous thrombosis: a study from India. *Blood Coagul Fibrinolysis* 2013;24(5):540–3.
 25. Akhtar N, Deleu D, Kamran S. Haematologic disorders and cerebral venous thrombosis. *J Pak Med Assoc* 2006;56(11):498–501.
 26. Koenig W. Haemostatic risk factors for cardiovascular diseases. *Eur Heart J* 1998;19(Suppl C):C39–43.
 27. Seguí R, Estellés A, Mira Y, España F, Villa P, Falcó C, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. *Br J Haematol* 2000;111(1):122–8.
 28. Zuluaga MI, Massaro M, Franco CA. Cerebral venous sinus thrombosis: Epidemiology, clinical characteristics, imaging and prognosis. *Biomedica* 2015;35(2):196–203. [Article in Spanish]
 29. Karsy M, Harmer JR, Guan J, Brock AA, Ravindra VM, Chung LS, et al. Outcomes in adults with cerebral venous sinus thrombosis: A retrospective cohort study. *J Clin Neurosci* 2018;53:34–40.